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ABSTRACT
Renal control of systemic phosphate homeostasis is critical as
evident from inborn and acquired diseases causing renal phos-
phate wasting. At least three transport proteins are responsible
for renal phosphate reabsorption: NAPI-IIa (SLC34A1), NAPI-
IIc (SLC34A3) and PIT-2 (SLC20A2). These transporters are
highly regulated by various cellular mechanisms and factors in-
cluding acid–base status, electrolyte balance and hormones such
as dopamine, glucocorticoids, growth factors, vitamin D3, para-
thyroid hormone and ﬁbroblast growth factor 23 (FGF23).
Whether renal phosphate wasting is caused by inactivating mu-
tations in the NAPI-IIa transporter is controversial. Mutations in
the NAPI-IIc transporter cause hereditary hypophosphatemic
rickets with hypercalciuria. Besides the primary inherited
defects, there are also inherited defects in major regulators of
phosphate homeostasis that lead to alterations in phosphate
handling. Autosomal dominant hypophosphatemic rickets is
due to FGF23 mutations leading to resistance against its own
degradation. Similarly, inactivating mutations in the PHEX gene,
which causes FGF23 inactivation, cause X-linked hypophospha-
temia due to renal phosphate losses. In contrast, mutations in
galactosamine:polypeptide N-acetyl-galactosaminyltransferase,
responsible for O-glycosylation of FGF23, or in klotho, a cofac-
tor for FGF23 signalling result in hyperphosphatemia. Acquired
syndromes of renal phosphate wasting, hypophosphatemia and
osteomalacia (tumour-associated osteomalacia) can be due to
the excessive synthesis or release of phosphaturic factors (FGF23,
FGF-7, MEPE and sFRP4) from mesenchymal tumours.
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INTRODUCTION
About 85% of total phosphate is deposited in bone and ∼10%
in soft tissues, the remaining 2–3% is found in serum,
constituting a freely exchangeable and tightly regulated phos-
phate pool. Serum phosphate levels in adults are maintained
in a narrow range of ∼0.8–1.45 mmol/L (2.4–4.5 mg/dL).
Deviations as found in patients with hypophosphatemia or
hyperphosphatemia can cause severe disturbances of cellular
and organ function such as ATP depletion, rickets, osteomal-
acia, anaemia or excessive tissue calciﬁcations, nephrolithiasis,
arteriosclerosis and increased risk of cardiovascular morbidity
and mortality [1–3].
Phosphate homeostasis is the product of intestinal uptake
of phosphate (in the range of 0.9–1 g/day) and reabsorption of
phosphate from urine (in the range of 60–80%). Both intes-
tinal uptake and renal reabsorption are mediated by sodium-
dependent phosphate cotransporters (Na+/Pi-cotransporters)
belonging to the SLC20 and SLC34 gene families of solute car-
riers [4, 5]. Their activity and expression is tightly regulated by
a large variety of hormones and metabolic factors adjusting
uptake and excretion to short and long-term body require-
ments. Inborn errors are caused by mutations in phosphate
transporters and in several genes that encode factors directly
and indirectly involved in their regulation. The identiﬁcation
of these genes and elucidation of their functions have greatly
contributed to our present understanding of how phosphate
homeostasis is achieved. This review will give a brief overview
over physiological function and regulation of renal phosphate
transporters. For more extensive reviews, the reader is referred
to a number of recent reviews and book chapters [5–9]. The
second part of this review will discuss mutations in several
genes that directly or indirectly participate in (renal) control of
phosphate balance.
General aspects of renal phosphate handling
About 80% of ﬁltered phosphate is reabsorbed from urine
under normal dietary phosphate intake by the earlier convoluted
parts of the proximal tubule of mostly juxtamedullary nephrons
[4]. Phosphate absorption is mediated by sodium-dependent
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cotransporters for inorganic phosphate (Pi) located in the brush
border membrane.
Three members of the Type II Na+-dependent phosphate
cotransporter family have been identiﬁed and classiﬁed in the
SLC34 solute carrier gene family [4]. SLC34A1 (NAPI-IIa) is
predominantly expressed in kidney mediating ∼70–80% of
overall phosphate reabsorption as suggested by a Slc34a1 deﬁ-
cient mouse model [10]. Another member of this family,
SLC34A3 (NAPI-IIc), is also almost exclusively found in
kidney [11]. SLC34A2 (NAPI-IIb) is mostly expressed in small
intestine and in a number of other organs including testis,
lung, liver and lactating mammary glands [12].
Also, sodium-dependent phosphate transporters from the
SLC20 family are expressed in the kidney. PIT-2 (SLC20A2) is
localized in the brush border membrane of the proximal
tubule whereas the exact site of expression of PIT-1 in kidney
is unclear [13]. PIT-2 is widely expressed in most tissues.
Its exact role in renal phosphate reabsorption has not been
clariﬁed but simultaneous genetic deletion of NaPi-IIa and
NaPi-IIc in mice reduced renal phosphate reabsorption by
>90%, suggesting that its contribution to overall phosphate
reabsorption may be minor [14]. PIT-2 is regulated by dietary
phosphate intake, acid–base status and parathyroid hormone
(PTH) [15, 16]. Mutations in PIT-2 have been described in pa-
tients with idiopathic basal ganglia calciﬁcation [17].
SLC34A1 (NaPi-IIa) and SLC34A3 (NaPi-IIc)
The human SLC34A1 gene lies on chromosome 5q35 [18],
is ∼13 kb in length and consists of 13 exons and 12 introns
[19]. Recently, a model for the protein structure of NAPI-IIa
was suggested based on homology modelling and detailed
structure–function studies [20].
The human SLC34A3 gene spans ∼5 kb containing 13
exons and lies on chromosome 9q34 [21, 22]. Human NAPI-
IIc contains 599 amino acids [21, 22]. NaPi-IIc expression in
mouse is stimulated in response to low-dietary phosphate
intake [23]. Also, dietary Pi-responsive elements (potential
TFE-3-binding sites) are located at −1846 and −1822 [23].
The transport functions of SLC34A transporters and their
structure–function relationship have been extensively studied
elucidating important features such as cotransport mode, elec-
trogenicity or voltage and pH-dependency [4]. Collectively,
these data demonstrate that NAPI-IIa transports three sodium
ions together with one divalent phosphate ion (HPO42) per
transport cycle. This transport mode is electrogenic [24, 25].
The transporter homodimerizes but the functional unit is a
monomer [26, 27]. The Type IIc cotransporter transports only
two sodium ions per phosphate and is electroneutral, indicat-
ing that divalent phosphate is its preferred substrate [28].
Regulation of renal phosphate reabsorption
A variety of factors affects renal phosphate handling as
listed in Table 1 [4, 29]. Alterations in the number of phos-
phate transporter molecules in the brush border membrane re-
present the main mechanism leading to changes in urinary
phosphate excretion [29]. The cellular and molecular mechan-
isms, by which NaPi-IIa and NaPi-IIc are regulated have been
extensively studied for PTH and changes in dietary phosphate
intake (for review, [4, 5]).
PTH rapidly induces phosphaturia within minutes by de-
creasing apical phosphate transport activity. Activation of PLC
by apical PTH receptors leads to protein kinase C dependent
stimulation of ERK1/2 kinases and internalization of NaPi-IIa
[29–31]. NaPi-IIa, apical PTH receptors and PLCβ1 are orga-
nized in a macromolecular complex via the PDZ-scaffold
protein NHE regulating factor 1 (NHERF1) [32–34]. In con-
trast, basolateral PTH receptors are linked to adenylate
cyclase, protein kinase A (PKA) and ERK1/2 [31]. NaPi-IIa is
not phosphorylated but dissociates from NHERF1, which is
phosphorylated in response to PTH [35, 36]. A similar mech-
anism has been proposed for ﬁbroblast growth factor 23
(FGF23)- and dopamine-induced endocytosis of NaPi-IIa [4].
The regulation of renal phosphate reabsorption by FGF23
is mediated by several mechanisms: FGF23 reduces circulating
levels of active 1,25(OH)2 vitamin D3 by reducing expression
of the activating enzyme CYP27B1 and by increasing expres-
sion of the inactivating enzyme CYP24A1 [37]. Lower active
vitamin D3 reduces the stimulation of renal and intestinal
phosphate (re)absorption. Moreover, renal phosphate re-
absorption is directly reduced by FGF23 through downregula-
tion of NaPiIIa and NaPiIIc. Two alternative but not exclusive
pathways have been proposed. FGF23 binds to FGF1c recep-
tors in the distal convoluted tubule, the main site of klotho ex-
pression in kidney leads to ERK1/2 phosphorylation and the
distal convoluted tubule then signals to the proximal tubule to
internalize NaPi-IIa and NaPi-IIc [38]. Alternatively, FGF23
may bind to FGF23 receptors in the proximal tubule and lead
to phosphorylation of NHERF1 via Sgk1 [39]. Also, a direct
regulation of NaPiIIa activity by klotho without FGF23 has
been demonstrated where klotho causes cleavage and inactiva-
tion of NaPi-IIa in the brush border membrane and subse-
quent internalization [40].
An acute reduction in NaPi-IIa transporters is mediated by
the internalization from the apical brush border membrane
via the same route as receptor-mediated endocytosis, requir-
ing megalin and involving clathrin-coated vesicles and early
endosomes [41, 42]. Consequently, NaPi-IIa is routed to lyso-
somes for degradation [43, 44]. The regulation of NaPi-IIc
has been studied in less detail: in response or high phosphate
NaPi-IIc downregulation occurs but is slower than for NaPi-
IIa [16, 45].
Table 1. Factors affecting phosphate reabsorption in the proximal tubule
Factors that decrease Pi reabsorption Factors that increase Pi
reabsorption
Acidosis
High-dietary Pi intake
Parathyroid hormone/cAMP
Atrial natriuretic peptide/cGMP
Glucocorticoids
Dopamine
Fibroblast growth factor 23
MEPE
Frizzled-related protein 4
Alkalosis
Low-dietary Pi intake
Parathyroidectomy
Thyroid hormone
1α,25(OH)2D3
Growth hormone(s)
Insulin-like growth factor
For explanation and references see text.
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Renal phosphate reabsorption closely matches dietary
phosphate intake being high during dietary phosphate restric-
tion and decreasing with high phosphate intake [11, 46–48].
In animals lacking PTH and/or 1,25(OH)2-vitamin D3, the
adaptive response of NaPi-IIa and NaPi-IIc is partially pre-
served, indicating that other factors may be responsible for
sensing and mediating changes in dietary phosphate intake
[49–51].
PRIMARY INHERITED DEFECTS IN RENAL
PHOSPHATE HANDLING
SLC34A1 (NAPI-IIa): hypophosphatemic
nephrolithiasis/osteoporosis-1 and Fanconi renotubular
syndrome-2
Two reports addressed patients with mutations in the
SLC34A1/NAPI-IIa gene. In the ﬁrst report, two patients with
urolithiasis or bone demineralization and persistent idiopathic
hypophosphatemia with lower maximal renal phosphate re-
absorption (TmP/GFR) were presented [52]. Single nucleotide
changes resulting in missense mutations (A48F and V147M)
were detected. These mutations were found only on one allele
per patient suggesting a dominant effect [52]. Expression of
the mutant NAPI-IIa transporters in oocytes has demonstrated
reduced phosphate transport activity, a dominant negative
effect on wild-type NAPI-IIa cotransporters, and reduced af-
ﬁnity for phosphate [52]. However, these data were controver-
sially discussed. SLC34A1 mutations were not conﬁrmed in
other kindreds with similar symptoms, relatives of patients
had not been genetically investigated and the expression assay
showed only low expression even for the wild-type transporter
rendering a kinetic analysis very difﬁcult. Moreover, expres-
sion of the reported mutant NAPI-IIa cotransporters in
Xenopus oocytes and the renal OK cell line did not show any
evidence for altered subcellular localization, levels of expres-
sion or reduced substrate afﬁnity [53], but showed a lower
transport activity. Yet, this decrease cannot fully explain the
massive phosphaturia observed. Therefore, it was suggested
that the nucleotide changes may represent only polymorph-
isms. A similar conclusion was derived from screening a large
number of pedigrees of calcium stone formers with low TmP/
GFR [54]. Even though a number of mutations including an
N-terminal deletion of seven amino acids (91del7) in the
NAPI-IIa gene were found, no correlation with the clinical
phenotype could be established. Two of the mutations had
lower phosphate transport activity after expression in Xenopus
oocytes, most likely due to decreased membrane abundance.
However, the reduction in transport rates was mild and im-
portantly, only one allele was found to be mutated in stone
forming patients. The interpretation that these mutations may
represent rather relatively common polymorphisms was
further supported by the fact that these gene alterations were
also found in several subjects with normal renal phosphate ex-
cretion. Thus, polymorphisms in the NAPI-IIa gene may be
relatively common and their relevance for renal phosphate
handling may require further clariﬁcation (Table 2).
A second report described siblings from a consanguineous
Arab Israeli family with hypophosphatemic rickets, multiple
fractures and stunted growth [55]. The presence of a Fanconi-
like syndrome was suggested, but hallmarks of a generalized
proximal tubule dysfunction are not evident from data re-
ported. The patients suffered from hypercalciuria due to ele-
vated serum 1,25(OH)2D3 levels. Hypophosphatemia was
refractory to vitamin D therapy. Genetic analysis detected a
homozygous in-frame duplication of 21 bp leading to inser-
tion of seven additional amino acids at position G154-V160.
Heterozygous carriers of the mutation were clinically normal
suggesting that the mutation did not exert a dominant negative
effect. Expression of the mutant protein in Xenopus oocytes
abolished all phosphate-induced currents whereas expression
in renal OK cells indicated failure of the mutant protein to
reach the plasma membrane.
Thus, homozygous mutations in SLC34A1 may be respon-
sible for renal phosphate wasting but whether this is only the
case for this speciﬁc mutation and may be due to toxic effects
of the mutant protein for proximal tubule functions or
whether mutations in this phosphate transporter can provide
evidence for the biological and clinical importance in human
kidney function remains to be established (Table 3).
SLC34A3 (NAPI-IIc): hereditary hypophosphatemic
rickets with hypercalciuria
Hereditary hypophosphatemic rickets with hypercalciuria
(HHRH) (OMIM #241530) is caused by mutations in the
SLC34A3 gene encoding for NAPI-IIc [21, 22]. The disease
was ﬁrst described in a Bedouin family [56] and is character-
ized by renal phosphate wasting causing hypophosphatemia
and secondary rickets, with elevated serum alkaline phosphat-
ase. Serum levels of 1,25(OH2)-vitamin D3 are high, PTH and
FGF23 are low, resulting in enhanced intestinal calcium absorp-
tion and subsequent renal excretion (hypercalciuria) promoting
nephrolithiasis or nephrocalcinosis in some patients [21, 22, 56,
57]. Long-term phosphate supplementation appears to reverse
the clinical and biochemical abnormalities in HHRH.
The SLC34A3 gene is localized on chromosome 9q34. Ob-
served mutations in HHRH include frame shifts in the open
reading frame with subsequent translation of sequences unre-
lated to NaPiIIc and premature termination, missense muta-
tions, intronic deletions and nucleotide changes in a putative
splice site [21, 22]. Inheritance follows an autosomal recessive
pattern [21, 22]. Some compound heterozygous patients carry-
ing two different missense mutations were also identiﬁed [21].
However, carriers with only one allele mutated show normal
phosphate balance and excretion but borderline or elevated
renal calcium excretion [21, 22].
Since NAPI-IIc mutations are associated with a severe renal
phosphate leak, NAPI-IIc may have a more important role in
human kidney function than in rodents. NAPI-IIc function in
man remains important during adulthood in contrast to
rodents where NaPi-IIc may play an important role only
during growth [11]. Accordingly, two mouse models of
Slc34a3 deﬁciency show only mild hypercalcuria without hy-
perphosphaturia or even no symptoms in the case of a kidney-
speciﬁc gene deletion [58, 59].
F
U
L
L
R
E
V
IE
W
G e n e t i c s o f r e n a l p h o s p h a t e h a n d l i n g iv47
Table 2. Genes/diseases causing altered renal phosphate handling
Gene Chromosome/
OMIM
Disease name Major symptoms Inheritance Tissue distribution of
protein
SLC34A1
(NaPiIIa)
5q35
OMIM#612286
OMIM#613388
Hypophosphatemic
nephrolithiasis/osteoporosis-1
(NPHLOP1)
Fanconi renotubular syndrome-2
(FRTS2)
Hypophosphatemia, urolithiasis,
osteoporosis?
Fanconi-like syndrome
Autosomal
dominant
Autosomal
recessive
Kidney (proximal
tubule)
SLC34A3
(NaPiIIc)
9q34
OMIM#241530
HHRH Hypophosphatemia, hyperphosphaturia,
rickets,
Hypercalciuria
Normal low FGF23, high 1,25-D3
Autosomal
recessive
Kidney (proximal
tubule)
SLC9A3R1
(NHERF1)
17q25.1
OMIM#612287
Hypophosphatemic
nephrolithiasis/osteoporosis-2
(NPHLOP2)
Hypophosphatemia
Hyperphosphaturia
Normal-low PTH
Mildy-elevated 1,25-D3
Nephrolithiasis
Autosomal
dominant
Kidney, intestine
FGF23 12p13.3
OMIM#193100
OMIM#211900
ADHR
FTC
Hyperphosphaturia
Hypophosphatemia
Rickets/osteomalacia
Normal 1,25-D3
High FGF23
Autosomal
dominant
Mainly bone
Klotho 13q13.1
OMIM#211900
FTC
Hypophosphatemic rickets with
hyperparathyroidism
Hyperphosphatemia
hypercalcemia
Heterotopic calciﬁcations
high-intact FGF23
high PTH
Hypophosphatemia
Hyperphosphaturia
High FGF23
High PTH
Autosomal
recessive
Translocation,
dominant
Kidney, parathyroid
gland, brain
PHEX Xp22.2-p22.1
OMIM#307800
XLH Hyperphosphaturia
Hypophosphatemia
Rickets/osteomalacia
Normal vitamin D
High FGF23
X-linked Mainly bone
GALNT3 2q24-q31
OMIM#211900
FTC Hyperphosphatemia
heterotopic calciﬁcation
Autosomal
recessive
Pancreas, testis
GNAS1 20q13.2
OMIM#174800
FD
(McCune–Albright syndrome)
Hyperphosphaturia, high-FGF23 levels,
polyostotic FD, pigmentation,
thyrotoxicosis, Cushing
Autosomal
dominant,
mosaicism
Ubiquitous
FAM20c 7p22.3
OMIM#259775
Raine syndrome
Osteosclerotic bone dysplasia
Increased bone density, periostal bone
growth
Skull deformation
Autosomal
recessive
Bone, kidney,
mammary gland, and
others
FGFR1 8p11.2-p11.1
OMIM#166250
Osteoglophonic dysplasia Hypophosphatemia
Hyperphosphaturia
Craniosynostosis
Autosomal
dominant?
Ubiquitous, bone,
kidney
DMP1 4q21
OMIM#241520
Autosomal recessive
hypophosphatemic rickets
Autosomal recessive
hypophosphatemia
Hypophosphatemia
Hyperphosphaturia
Rickets, osteomalacia
Autosomal
recessive
Ubiquitous,
Bone, heart, kidney
For explanation and references see text.
Table 3. Acquired forms of renal phosphate wasting
Gene/factor Chromosome/OMIM Disease Symptoms Occurrence Tissue distribution
sFRP4 7p14-p13
OMIM606570
TIO Hypophosphatemia
Hyperphosphaturia
Osteomalacia
Spontaneous? Tumour bone
FGF7 15q15-q21.1
OMIM148180
TIO Hypophosphatemia
Hyperphosphaturia
Osteomalacia
Spontaneous? Tumour
MEPE 4q21.1
OMIM605912
TIO Hypophosphatemia
Hyperphosphaturia
Osteomalacia
Spontaneous? Tumour, bone
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SLC9A3R1 (NHERF1): Na+/H+ exchanger regulating
factor 1: hypophosphatemic nephrolithiasis/
osteoporosis-2
NHERF1 mutations were detected in eight patients with
mildly reduced TmP/GFR, slightly lower serum phosphate levels,
nephrolithiasis in four of eight patients, lower bone mineral den-
sity in one patient, normal to low PTH and calcium values and
1,25(OH)2D3 just above the normal range in all patients. Four
NHERF1 mutations (E68A, L110V, R153Q and E225K) were
found. All patients were heterozygous [60, 61]. The mechanisms
by which mutant NHERF1 may cause phosphaturia may be site
speciﬁc. In the case of the L110V, R153Q and E225K mutations,
PTH- and cAMP-dependent inhibition of phosphate transport
may be increased, whereas the E68A mutation may reduce the
stability of the NaPiIIa transporter in the plasma membrane
leading, in all cases, to lower transport activities [60, 61].
DEFECTS IN RENAL PHOSPHATE HANDLING
SECONDARY TO EXTRARENAL INHERITED
DEFECTS
Fibroblast growth factor 23
FGF23 is primarily expressed in osteocytes [62–64]. Syn-
thesis and release of FGF23 from bone are increased during
hyperphosphatemia or high intake of phosphate [9, 65]. The
major functions of FGF23 are the inhibition of renal phos-
phate reabsorption by downregulation of NAPI-IIa and NAPI-
IIc expression and activity and by reducing the synthesis of
active vitamin D3 through lowering expression of the renal
CYP27B1 (1,25-alpha hydroxylase) and increasing CYP24A1
(1,24,25 hydroxylase). Lower concentrations of vitamin D3 de-
crease intestinal phosphate absorption. In addition, FGF23
suppresses PTH secretion. The effects of FGF23 on phosphate
homeostasis are mediated by ﬁbroblast growth factor receptor
1c (FGFR1c) and FGFR4 receptors and require klotho as an
obligatory co-ligand converting the low-afﬁnity receptors into
high-afﬁnity FGF23 receptors [9, 66].
Synthesis of FGF23 in osteocytes is regulated by a number of
factors including PTH, 1,25 vitamin D3 and a cascade of pro-
teins consisting of PHEX, 7B2/PC2, BMP1 and Dentin matrix
protein 1 (DMP1). PTH and 1,25 vitamin D3 transcriptionally
stimulate FGF23 production by mechanisms involving PKA/
Wnt and the VDR receptor, respectively [67, 68]. Activation of
this cascade increases proteolytic processing of DMP1 into N-
and C-terminal fragments, from which the latter is proposed to
blunt the transcription of FGF23 (for review, see [69]).
FGF23 is degraded by C-terminal cleavage most likely by
subtilisin-like proprotein convertases [70]. FGF23 possesses a
recognition site for cleavage by subtilisin-like proprotein con-
vertases consisting of an RXXR motif at position 176. A recent
report suggested that the PC2 proprotein convertase, com-
plexed with its chaperon 7B2, may mediate this process [71].
FGF23-activating mutations: autosomal dominant
hypophosphatemic rickets
Autosomal dominant hypophosphatemic rickets (ADHR)
(OMIM # 193100) is characterized by rickets, hypophosphatemia,
hyperphosphaturia, fatigue, bone pain and lower bone de-
formities in face of inappropriately low or normal vitamin D3
levels. ADHR is caused by mutations destroying the RXXR
cleavage motif mentioned above, causing excessive levels of
active FGF23 [72]. Similarly, injection of mice with wild-type
Fgf23 or Fgf23R179Q caused ADHR-like symptoms in mice.
Mutant Fgf23 caused hypophosphatemia, hyperphosphaturia,
reduced intestinal phosphate absorption and suppressed
serum vitamin D3 levels. In serum, high levels of mutant Fgf23
were detected, whereas wild-type Fgf23 was degraded [73].
Transgenic mice for Fgf23R176Q display typical ADHR symp-
toms and show signs of secondary hyperparathyroidism [74].
Thus, ADHR is caused by mutations in a motif important for
cleavage and degradation of FGF23 resulting in excessive
FGF23 signalling.
Loss-of-function FGF23 mutations: familial
tumoral calcinosis
Familial tumoral calcinosis (FTC) (OMIM # 211900) is the
mirror image of phosphate wasting diseases such as ADHR,
tumour-induced osteomalacia (TIO) and X-linked hypopho-
sphatemia (XLH). FTC is characterized by hyperphosphate-
mia, reduced renal phosphate excretion, ectopic calciﬁcations
and inappropriately normal or elevated 1,25(OH2) vitamin D3
levels. In a subset of FTC patients, a homozygous 211A-G
transition in the FGF23 gene was identiﬁed, resulting in the
substitution at an evolutionarily conserved serine to glycine
(S71G) [75]. This mutation may cause loss of function [75].
Patients have abnormally low-FGF23 plasma concentrations.
Mutant FGF23 protein expressed in vitro was not secreted and
retained intracellularly [75].
Fibrous dysplasia (McCune–Albright syndrome)
Fibrous dysplasia (FD) (OMIM #174800) is caused by non-
inherited genetic somatic activating missense mutations in the
α-subunit of the stimulatory G protein, Gs [76, 77]. FD is char-
acterized by abnormalities in bone (monostotic or polyostotic
FD), in skin (pigmentation) and in the endocrine system
(thyrotoxicosis, pituitary gigantism and Cushing syndrome).
The severity of disease and particularly the association with
skin and endocrine symptoms shows a wide variability. Renal
phosphate wasting is detected in ∼50% of patients [78]. FGF23
levels are elevated and caused by a large mass of FGF23-
producing cells in ﬁbrous bone lesions. Abnormal high-FGF23
levels are caused by an increase in FGF23-producing cells but
not by abnormal production of FGF23 per se [62, 79].
Klotho: FTC and hypophosphatemic rickets
with hyperparathyrodism
Mutations in the alpha-klotho (KL) gene can be another
reason for FTC besides mutations in galactosamine:polypep-
tide N-acetyl-galactosaminyltransferase (GALNT3) or loss-of-
function mutations in FGF23. A single patient with a missense
mutation was identiﬁed [80]. The mutation is predicted to
affect the glucosidase domain of klotho, which is involved in
the regulation of TRPV5 calcium channels [81]. Moreover,
reduced expression and glycosylation of klotho was demon-
strated, impairing the ability to interact with FGF23 and the
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FGF1R receptor. Accordingly, the patient had hyperphospha-
temia, increased vitamin D3 and PTH levels and ectopic calci-
ﬁcations of vessels.
The mirror image was described in another single case of a
balanced translocation between chromosomes 13 and 9 at a
position on chromosome 13 adjacent to the alpha-klotho
gene. The translocation massively increased circulating klotho
levels leading to hypophosphatemia, hyperphosphaturia, hy-
percalcaemia, elevated PTH and FGF23 and low vitamin D3
[82]. The elevated FGF23 levels may be explained by a feed-
back loop, by which circulating alpha klotho stimulates bone
FGF23 expression [83].
DMP1: autosomal recessive hypophosphatemic rickets
Patients with mutations in DMP1 suffer from hypopho-
sphatemia due to hyperphosphaturia with inappropriately
normal levels of 1,25(OH)2 vitamin D3 [84, 85]. DMP1
belongs to the large SIBLING family (small integrin-binding
ligand, N-linked glycoproteins) of extracellular matrix proteins
and is mainly co-expressed with FGF23 in bone. The similar
phenotype of patients with XLH and autosomal recessive hy-
pophosphatemia with rickets suggested a link to FGF23.
Indeed, in patients with loss of intact DMP1, FGF23 levels in
serum were normal or elevated [84, 85]. DMP1 (in particular
the C-terminal fragment) blocks the transcription of FGF23;
therefore, its absence may result in the release of this negative
control leading to higher FGF23 production. The hypopho-
sphatemia in DMP1 deﬁcient patients causes severe rickets in
children or osteomalacia in adults [84, 85], which is character-
ized by abnormal amounts of osteoid indicating defective min-
eralization and maturation of bone [85]. Similarly, a mouse
model deﬁcient for DMP1 shows hypophosphatemia, hyper-
phosphaturia, rickets, retarded skeletal growth with abnormal
mineralization, disturbed lacunocanicular organization and
defective osteoblast to osteocyte differentiation [85].
Tumour-induced osteomalacia
TIO is a rare paraneoplastic syndrome mostly associated
with mesenchymal tumours releasing (a) phosphaturic factor
(s). Symptoms include renal phosphate wasting causing hy-
pophosphatemia, osteomalacia and abnormal vitamin D
metabolism [86]. Surgical removal of the tumour reverses
symptoms. In contrast to syndromes of hyperparathyroidism
or humoral hypercalcaemia of malignancy, the plasma con-
centrations of calcium, PTH and PTH-related protein are
in the normal range. Several proteins, such as FGF23,
sFRP4, FGF-7 and matrix extracellular phospho-glycoprotein
(MEPE), have been identiﬁed that are produced and secreted
from tumours from patients with TIO. Some of these proteins
have been shown to regulate phosphate transport in vitro and/
or in vivo.
Secreted frizzled-related protein-4 (sFRP-4) is highly upre-
gulated in tumour tissue from patients with renal phosphate
wasting [87] and inhibits phosphate transport in the renal OK
cell line as well as in vivo [87, 88]. However, mice lacking sfrp4
do not show any abnormalities of systemic phosphate balance
[89]. Thus, the relevance of sFRP4 for phosphate homeostasis
remains to be further clariﬁed.
MEPE: oncogenic hypophosphatemia
MEPE, a glycosylated protein of about 60 kDa, was initially
cloned from tumour tissue obtained from a patient with onco-
genic hypophosphatemia [90]. Bone cells (osteoblasts, osteo-
cytes and odontoblasts) are the major source of MEPE.
MEPE-like DMP1 is another member of the SIBLING family
of extracellular matrix proteins involved in bone regulation.
Injection of MEPE into intact mice results in hypophosphate-
mia, hyperphosphaturia and mild increases in circulating 1,25
(OH)2 vitamin D3 levels [91]. Moreover, implantation of
MEPE-producing CHO cells into nude mice caused renal
phosphate wasting, whereas MEPE deﬁcient mice have higher
bone density [92]. The interactions between MEPE and other
hormones regulating phosphate homeostasis and handling
require more investigation.
PHEX: XLH rickets
XLH rickets (OMIM #307800) is the most common herit-
able form of rickets with a prevalence of ∼1 in 20 000. The
disease is characterized by hypophosphatemia due to excessive
renal phosphate wasting leading to rickets, lower extremities
deformity, short stature, bone and joint pain, enthesopathy
and dental abscesses. Vitamin D3 levels are inappropriately
normal or even low [93]. The disorder is inherited in a domin-
ant manner. Positional cloning identiﬁed the PHEX gene
(PHosphate regulating gene with homology to Endopeptidases
on the X chromosome) in XLH patients [93]. Several mouse
models of XLH are available: Hyp, Gy and Ska1 mice resem-
bling XLH and which were later shown to have mutations in
the mouse Phex homologue [94–96]. The X-linked Hypmouse
model demonstrates a defect in proximal tubular phosphate
absorption, decreased expression of NaPi-IIa and NaPi-IIc
[97–99]. Serum FGF23 levels are highly elevated in XLH pa-
tients [100]. Crossing of hypophosphatemic Hyp mice with
hyperphosphatemic Fgf23 deﬁcient mice produced hyperpho-
sphatemic mice that showed exactly the same phenotype as
Fgf23 null mice, indicating that both mutations affect the same
system and that FGF23 may act downstream of PHEX [101].
Observations in Hyp and FGF23 null mice indicate that PHEX
and FGF23 may regulate each other’s expression levels and
that loss of PHEX may lead to higher expression levels of
FGF23 [63, 65]. Although originally proposed, PHEX seems
not to mediate direct cleavage of FGF23 [63, 70]. Instead,
PHEX may activate the PC2 proprotein convertase by promot-
ing the transcription of its 7B2 chaperon [71]. Transfection of
osteoblast with 7B2.PC2 promoted cleavage of FGF23,
whereas depletion of 7B2 mRNA reduced FGF23 cleavage and
increased its transcription. The activated FGF23 transcription
seems to result from an impaired proteolytic processing of
DMP1 (see above). In agreement with this model, the mRNA
levels of 7B2 are reduced in bones from Hyp mice [71].
UDP-N-acetyl-α-D GALNT3: FTC
Homozygous loss-of-function mutations of the UDP-N-
acetyl-α-D GALNT3, a glycosyltransferase involved in mucin-
type O-glycosylation, underlie also FTC (OMIM # 211900)
[102, 103]. However, patients carrying only one mutated allele
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appear to also have mild symptoms, leading to the initial de-
scription of FTC as an autosomal dominant disease [104].
Because inactivating mutations in FGF23 also cause FTC and
FGF23 has some O-glycosylation sites within the subtilisin-
recognition sites, it had been speculated that GALNT3 is crit-
ical for FGF23 gylcosylation and full function. Accordingly,
in vitro secretion of FGF23 from CHO cells deﬁcient in O-
glycosylation is impaired, and cotransfection of GALNT3
markedly increases O-glycosylation and secretion of FGF23.
Thus, GALNT3 may play an important role in FGF23 secre-
tion by mediating its O-glycosylation [105]. This function may
also explain how loss of function mutations in either FGF23 or
GALNT3 can produce the same disease, FTC.
Fibroblast growth factor receptor 1: osteoglophonic
dysplasia
Osteoglophonic dysplasia (OMIM #166250) is caused by
mutations in the FGFR1 that result in a gain-of-function and
activation of the receptor [106]. Patients suffer from craniosy-
nostosis, prominent supraorbital ridge and depressed nasal
bridge, as well as from rhizomelic dwarﬁsm and nonossifying
bone lesions. Several missense mutations in the FGFR1 gene
were identiﬁed in four patients. Three patients were hypopho-
sphatemic due to massive renal phosphate wasting [106]. One
patient had inappropriately high-FGF23 levels, two patients
had high 1,25(OH)2 vitamin D3 levels. As two related patients
carried the Y372C FGFR1mutation. The activity of the mutant
receptor was highly increased suggesting that overactivity of
the FGF1 receptor is responsible for this disease [106]. The
FGFR1 receptor mediates the downregulation of NAPI-IIa and
NAPI-IIc by FGF23, whereas the effects of FGF23 on vitamin
D3 metabolism may involve the FGFR4 receptor [66].
FAM20C: Raine syndrome (osteosclerotic
bone dysplasia)
Raine syndrome is caused by mutations in the protein
kinase FAM20C, which resides in the Golgi apparatus and is
secreted [107, 108]. Patients develop generalized higher bone
density with characteristic changes and enhancement of the
ossiﬁcation of the skull, cerebral calciﬁcation and in some
cases hypoplastic lungs. The disease is often lethal in the ﬁrst
weeks after birth but patients with longer survival reaching
into puberty have been described. The renal phenotype of pa-
tients with Raine syndrome has not been reported in detail.
Targets phosphorylated by FAM20C are casein, osteoproteger-
in, DMP1 and MEPE, members of the SIBLING family. In
Fam20c deﬁcient mice, hypophosphatemic rickets was ob-
served possibly due to dysregulation of FGF23 (which is very
high) due to lack of DMP1 phosphorylation [109].
CONCLUSION AND OUTLOOK
Renal and extrarenal control of systemic phosphate homeo-
stasis requires a complicated network of regulatory factors,
phosphate transporters in kidney, intestine and bone and
intracellular protein–protein interactions. Rare human genetic
disorders and mouse genetics have greatly contributed to our
current understanding of (renal) phosphate homeostasis. Im-
portantly, population-based genome-wide association studies
identiﬁed SLC34A1 and FGF23 as important determinants of
plasma phosphate levels [110]. Moreover, the highly elevated
FGF23 levels in patients with various types of chronic kidney
disease and the potential link between FGF23 and cardiovas-
cular disease in these patients underline even further the bio-
logical importance of this homeostatic system for health and
disease. Nevertheless, our understanding of key elements of
this system is incomplete and we require deeper insights on
how organs and cells sense phosphate and how changes in sys-
temic phosphate levels can trigger disease. The identiﬁcation
of key players through genetics may also pave the way for ther-
apies targeting disturbed phosphate balance in both rare in-
herited disorders as well as in more common diseases such as
chronic kidney disease.
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